You are here:

cinacalcet (Mimpara)

Advice

In the absence of a submission from the holder of the marketing authorisation.

cinacalcet 30mg, 60mg & 90mg (Mimpara®) is not recommended for use within NHSScotland for the reduction of hypercalcaemia in patients with primary hyperparathyroidism (HPT) for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: cinacalcet (Mimpara)
SMC Drug ID: 513/08
Manufacturer: Amgen Ltd
Indication: For the reduction of hypercalcaemia in patients with primary hyperparathyroidism (HPT)
BNF Category:
Sub Category: 6.6 Drugs affecting bone metabolism
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 13 October 2008

Back